KARE is a pilot trial investigating if ketamine combined with talk therapy may help people who are looking to reduce their methamphetamine use and risks of acquiring or transmitting HIV.

The intervention is three office-based doses of injection ketamine combined with seven talk therapy visits. Researchers believe this combination may help to make it easier to stop or reduce methamphetamine use. 

To see if you may be eligible to participate, call us at 628.217.6319 or send us your contact information using the contact form on this page. Someone  from our team will contact you to see if you may be eligible to come into our office. If you are, we will set up your screening visit.  

The screening process can take up to four weeks to determine if you are eligible  to participate. This process includes meeting with a research associate, clinical  staff and various other procedures, which will be explained to you during the  informed consent process.

If you are eligible and choose to participate, you will be asked to attend about 2 visits each week for abut 5 weeks, then 2 follow-up visits about 4 and 12 weeks thereafter. The visits will occur at our office at Market St. and Van Ness in San Francisco.

 Yes. Your time and contribution are of tremendous value to public health  research. If you are eligible, you can earn up to $575 for completing all study  activities and procedures.